Agoracom Blog Home

Author Archive

« Older Entries
Newer Entries »

Liquid Avatar and The $KABN.ca Network Launch Cloud-based #Biometric Identity Verification for Self Sovereign Identity, Digital Wallets and Verified Credentials $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 9:24 AM on Wednesday, December 2nd, 2020
kabn-square-new
  • Announced that its cloud-based biometric solutions will now be available on its digital identity management platform, Liquid Avatar (www.liquidavatar.com) enabling a further layer of identity verification that is independent of a user’s device
  • As a cloud-based service, KABN’s biometric features are not resident on a device and work with a user’s mobile phone, tablet, computer or other camera and Internet enabled devices, to pass verified information securely over the Internet, enabling identity to be transportable and connected to a wide range of applications like Passwords, Digital Wallets and Verified Access and Identity Credentials

TORONTO, ON and GIBRALTAR / December 2, 2020 / The KABN Network together with KABN Systems NA Holdings Corp. (CSE:KABN) (the “Company” or “KABN North America“), a Canadian fintech company that specializes in continuous online identity verification, management and monetization in Canada and the US, today announces that its cloud-based biometric solutions will now be available on its digital identity management platform, Liquid Avatar (www.liquidavatar.com) enabling a further layer of identity verification that is independent of a user’s device.

“With more traditional services, like healthcare, education, verified purchasing and government services expanding online, we developed Liquid Avatar to allow users to use their verified identity to share what they want, when they want and with whom they want in an easy to use visually-enabled platform,” said David Lucatch, CEO KABN North America. “Our goal is to reduce and, in some cases, eliminate the need to remember passwords or to present physical credentials in an ever expanding digital landscape. We hope to empower users to seamlessly manage their digital lives as easily and effectively as they do conventionally.”

As a cloud-based service, KABN’s biometric features are not resident on a device and work with a user’s mobile phone, tablet, computer or other camera and Internet enabled devices, to pass verified information securely over the Internet, enabling identity to be transportable and connected to a wide range of applications like Passwords, Digital Wallets and Verified Access and Identity Credentials.

With Liquid Avatar’s Self Sovereign Identity management services, a user can manage and customize their credentials through easy to access “icons,” enabling them to store, organize and control their information remotely, increasing potential security and safety in the event that the device is lost, stolen or compromised, and making it easy to share services using their facial recognition or other biometric controls.

Liquid Avatar will work with a wide range of emerging technologies and digital platforms to enable the creation and support of a wide range of services, such as:

Identity Verification Services – Bank Grade Identity and Biometric Verification
Digital Wallet Applications – Crypto and Digital Currencies, Identity, Credentials
Verified Access Credentials – Concerts, Movies, Theme Parks, Senior Living, Sporting and other Venue Events and Facilities
Verified Identity Credentials – Government, Healthcare, eCommerce, Membership, School, Workplace and other

Guardianship Services – In early 2021, Liquid Avatar will enable users to authorize a secondary “guardian” for biometric data access. Ideal for parents that want to protect and authorize certain activities for their children, like education, online gaming, eCommerce and other activities. This service can also be used as a safeguard in cases of emergency allowing an authorized second, biometrically verified person, to access a user’s data.

“In the real world, we recognize and verify each other using personal recognition, and document verification and we believe that Liquid Avatar can potentially duplicate this process in the digital world,” continued Lucatch.

In the coming weeks, the Company is expecting to rollout a number of key initiatives that will support the creation, management and verification of digital wallets and verified access and identity credentials.

About KABN North America – www.kabnnaholdco.com

KABN Systems NA Holdings Corp. through its wholly owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from the use of their online identity. KABN’s propriety technology suite includes 4 key products:

Liquid Avatar allows users to create high quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allow users to manage and control their Digital Identity and to use Liquid Avatars to share public and permission based private data when they want and with whom they want. www.liquidavatar.com

KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community.

KABN Systems NA Holdings Corp. is a publicly listed company on the Canadian Securities Exchange (“CSE”) under the symbol “KABN.”

For more information, please visit www.kabnnaholdco.com or www.kabnsystemsna.com.

For further information, please contact:

David Lucatch
Chief Executive Officer
647-725-7742 Ext. 701
[email protected]

Media Contact:

Nicole Rodrigues
NRPR Group
[email protected]

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the KABN Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “is expected,” “budget,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or may contain statements that certain actions, events or results “may,” “could,” “would,” “might” or “will be taken,” “will continue,” “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, information concerning the ability of the Company to generate revenues, roll out new programs and to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

Tags: , , , , , , , , ,
Posted in Featured, KABN, KABN Systems NA Holdings Corp. | Comments Off on Liquid Avatar and The $KABN.ca Network Launch Cloud-based #Biometric Identity Verification for Self Sovereign Identity, Digital Wallets and Verified Credentials $MOS.ca $MOGO.ca $CTZ.ca

Datametrex $DM.ca $DTMXF Provides Update on the 1copy(TM) COVID-19 Test Kit and Announces Investor Webinar $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 8:12 AM on Wednesday, December 2nd, 2020
Webinar logo
  • Announced that the manufacturer of 1copy™ COVID-19 qPCR Multi Kit (“qPCR kit”) has made available the new testing method and technology with improvements related to testing time.
  • The qPCR kit has reduced the processing time with a polymerase chain reaction (“PCR”) machine to 45-50 minutes.
  • This is significant compared to other test kits available in the market for the same category of tests that can take up to 2 hours for similar test results.
  • As a result, management of the Company anticipates that this will help in the service of the Company’s current projects especially when processing large film crews which will enhance the turnaround times for test results on these multi-million dollar productions.

Toronto, Ontario–(December 2, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that the manufacturer of 1copy™ COVID-19 qPCR Multi Kit (“qPCR kit”) has made available the new testing method and technology with improvements related to testing time.

The qPCR kit has reduced the processing time with a polymerase chain reaction (“PCR”) machine to 45-50 minutes. This is significant compared to other test kits available in the market for the same category of tests that can take up to 2 hours for similar test results. As a result, management of the Company anticipates that this will help in the service of the Company’s current projects especially when processing large film crews which will enhance the turnaround times for test results on these multi-million dollar productions.

The Company also sees a benefit of rapid results as it navigates into the travel industry as it looks at processing passengers at cruise ship terminals, and with airport authorities, to reduce the risk of transmission of the virus. These potential testing projects represent an important shift towards getting the travel industry back on its feet over the next year and supporting business travellers and vacationers looking to safely take a trip abroad.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

Investor Webinar

Datametrex also announces that its senior management will be hosting an investor update webinar on Thursday, December 3, 2020, at 1:30 p.m. EST to discuss the Company’s Third Quarter 2020 results, developments, and contracts on the Artificial Intelligence technologies and COVID-19 test kits.

Webinar Details:

Date: Thursday, December 3, 2020

Time: 1:30 p.m. ET

Registration Link: https://us02web.zoom.us/webinar/register/8016064291474/WN_W-6UeDO8Tpu8yaAyn43OLg

Datametrex plans to answer questions previously sent to [email protected] and during the webinar, at management’s discretion and subject to time constraints.

The Company’s Financial Statements (“FS”)and Management Discussion & Analysis (“MD&A”) are available at the nine months ended September 30, 2020 are available on the Company’s profile at SEDAR at www.sedar.com.

About 1drop Inc.

1copy™ COVID-19 qPCR Kit is approved by Health Canada (“HC”), Kingdom of Saudi Arabia-Saudi Food & Drug Authority (“SFDA”) approval, and CE marking certification (“CE”) for European Economic Area (“EEA”) countries, which covers the 27 member states of the EU, the 4 members of the European Free Tarde Association (the “EFTA”), plus Turkey and the United Kingdom under Brexit. It is a nucleic test kit that verifies RdRp gene for SARS-CoV-2 with the qPCR kit via nasopharyngeal swab and oropharyngeal swab and specifically targeting the E gene sequences of COVID-19. The kits are made by 1drop Inc. located in Jungwon-gu, South Korea, and was incorporated in 2017 following a technology spin-off from Samsung electronica’s C-Lab program. Samsung Electronica’s C-Lab located in South Korea is an internal incubation program that first started in 2012 to help inspire a more creative company culture.

For more information please consult the website at: 1drop

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.

Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.

Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Tags: , , , , , , , ,
Posted in Datametrex AI Limited, Featured | Comments Off on Datametrex $DM.ca $DTMXF Provides Update on the 1copy(TM) COVID-19 Test Kit and Announces Investor Webinar $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab to Launch FDA Approved Saliva-Based COVID-19 Test December 15. Previously Announced ABC-PCR Test Launches with Film & Tv Testing Contract Increasing To 10,000 Units Commencing December 7. $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:35 AM on Wednesday, December 2nd, 2020
  • Announced that Kai Medical Laboratory (“KAI”) will be launching an FDA approved, at home/work saliva COVID-19 RT-PCR test (“Saliva Test”) on December 15th.
  • In addition, the Company’s previously announced KAI ABC-PCR test protocol to simultaneously differentiate between Influenza A/B and COVID-19 (“ABC”), will be launching on December 7th, with our record film & tv production contract switching to KAI ABC PCR and increasing the number of test units to 10,000.

VANCOUVER, BC / December 2, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) will be launching an FDA approved, at home/work saliva COVID-19 RT-PCR test (“Saliva Test”) on December 15th.

In addition, the Company’s previously announced KAI ABC-PCR test protocol to simultaneously differentiate between Influenza A/B and COVID-19 (“ABC”), will be launching on December 7th, with our record film & tv production contract switching to KAI ABC PCR and increasing the number of test units to 10,000.

FDA APPROVED “SPIT AND SHAKE” AT HOME/WORK SALIVA TEST IS A GAME CHANGER

The KAI Saliva Test is the direct result of investing in scientific R&D through KAI, empowering them to deliver clinical trial data and validation. This gives Empower a strong upper hand nationally and now potentially on an international stage.

The power of the Saliva Test is in its simplicity, in which users merely spit into a funnel, then close the funnel with a lid containing a liquid to be mixed with the saliva by simply shaking it for 5 seconds. This saliva based PCR test does not require a medical technician to administer the specimen collection which can be done by the individual, a parent or an administrator. The specimen is returned to KAI Medical Labs from anywhere in the country for processing. KAI will analyze and provide a response within 24 hours through its HIPAA compliant IT system.

Empower Clinics CEO, Steven McAuley stated “The new KAI Saliva Test is an anywhere-based PCR test that is non-invasive and can even be used to test children. It’s simple, effective and can be distributed nationwide with FDA approval using the KAI assay and processing procedures. It is a game changer in its simplicity and we are optimistic about its success.”

The KAI Saliva Test will be available for sale December 15th, with distribution expected to comprise of online access, wholesale programs and available through our clinic group Sun Valley Health.

KAI ABC RT-PCR TEST PROTOCOL TO DIFFERENTIATE BETWEEN INFLUENZA A/B AND COVID-19 (“ABC”) LAUNCHES WITH RECORD ORDER FROM FILM & TV PRODUCTION

On November 19th, Empower announced Kai Medical Lab to Introduce New Influenza A/B COVID RT-PCR Test to Differentiate Influenza From COVID-19, which will be vital in the diagnosis and treatment of respiratory pathogens.

Furthermore, Empower confirmed in that press release that the record order received from a film & television production for 9,000 tests is in excess of $1,000,000 would be switching to the higher priced ABC RT-PCR Test.

LAUNCH DATE OF COVID-19 ABC RT-PCR TEST MAKES KAI A LEADING NATIONAL MEDICAL LABORATORY

Given the fact that household named labs have not been able to begin distributing their form of an ABC PCR test, the KAI launch date and record order for its ABC RT-PCR test makes KAI Medical Labs a national leader in COVID-19 testing. As a result, Empower has filed a trademark for KAI ABC PCR.

Empower CEO McAuley added “The requirements for more diverse and flexible testing protocols solving complex operational requirements for consumers, industry, private and public sectors form the scientific R&D focus for KAI Medical, as we lead trials and validation for the latest COVID-19 tests.”

Having these new simplified and highly accurate “gold standard” RT-PCR tests opens up markets by breaking down barriers to enable industries to get back to business again, while enabling the public sector to deliver the services of the government that countries depend upon.

MULTIPLE BENEFITS OF KAI ABC RT-PCR RANGE FROM EARLY AND CORRECT DIAGNOSIS TO PACKAGED COST SAVINGS

COVID-19 and influenza viruses have a similar disease presentation. They both cause respiratory disease, which presents as a wide range of illness from asymptomatic or mild through to severe disease and death. As such, the benefits of this KAI ABC PCR test protocol being able to differentiate between the Flu and COVID-19 are invaluable as follows:

First, it is vital in the diagnosis and treatment of respiratory pathogens. As most COVID-19 testing now primarily focuses on COVID-19 only, diagnosing the difference between the two will be crucial to treatment, health outcomes, and overall health of the population. Specifically, differentiating the pathogens will help medical professionals quickly diagnose and treat more efficiently & efficaciously.

Second, it is a vital tool in helping slow down the spread of COVID-19. Specifically, the speed of transmission is an important point of difference between the two viruses. Influenza has a shorter median incubation period (the time from infection to appearance of symptoms) than COVID-19. Transmission in the first 3-5 days of illness is a major driver for the spread of viral infections. This makes COVID-19 extremely difficult to contain. This is why testing to differentiate the viral infections becomes critical to “slowing the spread.”

Finally, affordability and efficiency. Though the overall cost of an ABC RT-PCR test is approximately 15% to 25% more expensive than an RT-PCR test, providing analysis on all three viruses is significantly cheaper and more affordable than testing for them separately. Moreover, from an efficiency point of view, simultaneously confirming a patient has the flu and does not have COVID-19 from the same collected specimen, allows them, their families and work colleagues to return to a normal life much faster.

BENEFITS TO EMPOWER CLINICS

From a business development point of view, Empower has a high degree of confidence the multiple benefits listed above will translate into significant new business, as evidenced already by the transition of the Company’s recent $1,000,000 test order by a film & tv production from RT-PCR to the new KAI ABC PCR protocol.

From an R&D perspective, Kai Medical Laboratory is focused on the future and new innovative quality testing to better understand the epidemiology and contagion containment that we have all experienced during this pandemic. Kai Medical will continue to be at the forefront of science and innovative quality care by providing value added services, accuracy, and consistency. As such, we believe more successful R&D product announcements will be made in the near future.

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab to Launch FDA Approved Saliva-Based COVID-19 Test December 15. Previously Announced ABC-PCR Test Launches with Film & Tv Testing Contract Increasing To 10,000 Units Commencing December 7. $WELL.ca $DOC.ca $DOCRF $VMD.ca

Innocan $INNO.ca Reports Q3 2020 Financial Results $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 7:30 AM on Wednesday, December 2nd, 2020
Innocan-Blog

The following is a summary of key balance sheet items as of September 30, 2020, as compared to figures as at December 31, 2019:

  • Cash and cash equivalents were C$2,393,060 as compared to C$2,569,602;
  • Current assets of C$3.6 million as compared to C$3.2 million;
  • Total assets of C$3.7 million as compared to C$3.3 million; and
  • Current liabilities of C$3.07 million as compared to C$1.4 million.

Herzliya, Israel and Calgary, Alberta–(December 2, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today its financial and business results for the three and nine months period ended September 30, 2020 (the “Financial Statements“) and provide highlights and comments on these results. This news release should be read in conjunction with the Financial Statements and corresponding Management’s Discussion and Analysis available on the Company’s profile at www.sedar.com. The Company’s Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRS“).

“This has been a milestone quarter for Innocan. After successfully completing our $5.1M financing, we have laid the groundwork for full commercialization of our CBD based products. We are completing the manufacturing process in Europe and the USA and have received regulatory approvals for marketing in Europe and the USA” stated Iris Bincovich, Chief Executive Officer of Innocan.”

Business highlights for the three months period ended September 30, 2020

On June 5, 2020, the Company announced the commencement of commercial production of its Derma CBD line in Portugal. The first product currently being manufactured is the patent pending Relief & Go Pain Relief spray.

On June 26, 2020, the Company announced the results from the first dermal clinical study of the Relief & Go and SHIR product lines. The double-blind, randomized control study assessed the tolerance degree of the Company’s CBD topical products and demonstrated the products to be non-irritating to the skin.

On July 9, 2020, the Company announced its collaboration with Recipharm, Israel (“Recipharm“) to synthesize and analyze cannabinoid loaded exosomes. Recipharm unites more than 30 facilities across 10 countries offering a range of services with a focus on two areas of operation: pharmaceutical development services and manufacturing services.

On July 13, 2020, the Company announced that it received notice from the U.S. Food and Drug Administration that Innocan’s over-the-counter Relief & Go Pain Relief spray received technical validation and approval to commence marketing in the USA. Innocan’s pain relief formulation contains a combination of magnesium oil, methyl salicylate, menthol and CBD. The Relief & Go Pain Relief spray is designed to target and relieve pain related to muscles and joints. The unique formulation is administered with a simple dose by spray, roll-on or lotion.

On August 6, 2020, the Company announced that its SHIR CBD Derma Cosmetic product line successfully passed safety assessments in accordance with European Union (EU) cosmetic regulation No. 1223/2009 and received an EU Cosmetic Product Safety Report for marketing in the European Union.

On August 11, 2020, the Company announced it entered into a manufacturing and distribution agreement (the “ESI Agreement“) with Endless Sky Incorporated (“ESI“), a large-scale Canadian cannabis extractor based in Calgary, Alberta. Under the ESI Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan. ESI’s manufacturing and distribution rights consist of the Relief & Go Pain Relief spray and cream and the SHIR Eye Serum, Face Cream and Night Cream. The ESI Agreement is conditional upon ESI receiving Health Canada approval no later than December 31, 2020. According to the ESI agreement, ESI shall pay Innocan a cash license fee per product as well as royalties based on net sales of the products distributed by ESI. The ESI Agreement is for a term of 12 months and will be automatically extended for additional periods of 12 months, each based on ESI achieving minimum sales targets for the previous 12-month period.

On August 19, 2020, the Company entered into a manufacture and supply agreement with GNB Swiss Investments SA to manufacture and supply GNB Swiss Investments SA products based on Innocan’s formulas, which will be distributed by GNB Swiss Investments SA under its own brand.

On August 20, 2020, the Company announced that Innocan entered into a distribution agreement (the “Cloud 9 Agreement“) with Cloud 9 Switzerland LLC (“Cloud 9“) to sell the Company’s SHIR Beauty and Relief & Go product lines in Italy and Switzerland. Under the terms of the Cloud 9 Agreement, Cloud 9 will distribute Innocan’s unique cosmetic CBD products in Italy and Switzerland on a nonexclusive basis. The Cloud 9 Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties. The parties intend to carry out the Cloud 9 Agreement immediately, following the completion of all registration and regulatory requirements in Italy and Switzerland.

On September 15, 2020, the Company announced it completed a cosmetic clinical study examining the impact of its SHIR Premium CBD Facial Serum, containing 300 mg of cannabidiol, on skin hydration.

Financial highlights for the three months period ended September 30, 2020, compared to the three months period ended September 30, 2019:

The following are financial highlights of Innocan’s operating results for the three months period ended September 30, 2020, compared to the three months period ended September 30, 2019:

Research and development expenses amounted to C$654,000 for the three months period ended September 30, 2020 compared to C$149,000 for the three months period ended September 30, 2019. The increase is primarily attributable to an increase in research expenses due to the new research agreements entered into during the nine months period ended September 30, 2020 with Yissum Research Development Company and Ramot at Tel Aviv University, along with an increase in patent application expenses.

Selling, general and administrative expenses amounted to C$902,000 for the three months period ended September 30, 2020 compared to C$1,858,000 for the three months period ended September 30, 2019. The decrease in selling, general and administrative expenses is primarily attributable to the reduction of issuance expenses.

The following is a summary of key balance sheet items as of September 30, 2020, as compared to figures as at December 31, 2019:

  • Cash and cash equivalents were C$2,393,060 as compared to C$2,569,602;
  • Current assets of C$3.6 million as compared to C$3.2 million;
  • Total assets of C$3.7 million as compared to C$3.3 million; and
  • Current liabilities of C$3.07 million as compared to C$1.4 million.

About Innocan

The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

Innocan signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique controlled release liposome to be administrated by injection. Innocan plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research at the Hebrew University, to test the liposome platform on several potential indications. Innocan is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

Iris Bincovich, CEO
+972-54-3012842
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Tags: , , , , , , , ,
Posted in Innocan Pharma Corporation | Comments Off on Innocan $INNO.ca Reports Q3 2020 Financial Results $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Universal PropTech Inc. $UPI.ca Names Frank Carnevale as Chief Growth Officer $SNE $MSFT $HON $SONA.ca

Posted by AGORACOM-JC at 4:24 PM on Tuesday, December 1st, 2020
  • Announced the appointment of Mr. Frank Carnevale as Chief Growth Officer.
  • Mr Carnevale is the former Chief Operating Officer of the Company, and is returning to focus on acquisitions, investments, organic growth strategies and execution to improve the overall value of the Company.
  • Mr. Carnevale will work closely with the CEO, Mr. Chris Hazelton, in delivering an aggressive growth program over the coming months.

Toronto, Ontario–(December 1, 2020) – Universal PropTech Inc. (TSXV: UPI) (“the Company”) is pleased to announce the appointment of Mr. Frank Carnevale as Chief Growth Officer.

Mr Carnevale is the former Chief Operating Officer of the Company, and is returning to focus on acquisitions, investments, organic growth strategies and execution to improve the overall value of the Company. Mr. Carnevale will work closely with the CEO, Mr. Chris Hazelton, in delivering an aggressive growth program over the coming months.

Mr. Carnevale is an award-winning CxO, industry thought leader, and has originated over $2.5 billion in energy transactions in regulated and unregulated energy service companies. He served as an Executive Board Member of the Energy Council of Canada from 2017 to 2019. He also served as a Board Member of the Council for Clean & Reliable Electricity, and the Ontario Energy Association.

“I see tremendous opportunities to improve the value of facilities by integrating proptech innovation with design, operations, and all in a very holistic customer-centric approach,” commented Frank Carnevale, Chief Growth Officer of Universal PropTech Inc.

“We are excited to have Frank back with us to aggressively grow our businesses,” stated Chris Hazelton, Chief Executive of Officer of Universal PropTech Inc. “He brings a unique perspective on how to take our share of the ongoing transformation in proptech and energy.”

About Universal PropTech Inc.

Universal PropTech Inc. (TSXV: UPI), conducts its operations through its wholly-owned subsidiary, VCI Controls Inc. (“VCI”), a leading supplier and integrator of proptech healthy building solutions and services. The Company is an industry leader in the development of intelligent building technology, including the integration of all building systems utilizing the latest in communications technologies and standards. VCI’s business focuses on digital controls and mechanical services, performance monitoring, and energy efficiency solutions.

With headquarters in Toronto, Universal PropTech has offices across Canada including, Halifax, Montreal, and Ottawa. For more information, visit www.universalproptech.com

Certain statements in this press release are forward-looking statements. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Forward-looking statements, specifically those concerning future performance and other statements that are not historical fact, are subject to certain risks and uncertainties, and actual results may differ materially from the Company’s plans and expectations. These plans, expectations, risks and uncertainties are detailed herein and from time to time in the filings made by the Company with the TSX Venture Exchange (the “Exchange”) and securities regulators. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Trading in the securities of the Company should be considered highly speculative. All forward-looking information contained in this news release is expressly qualified in its entirety by this cautionary statement.

Neither the Exchange, nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

CONTACT INFORMATION

Universal PropTech Inc.

Chris Hazelton

Chief Executive Officer

(647) 300-2957

Tags: , , , , , , , , , ,
Posted in Universal PropTech Inc. | Comments Off on Universal PropTech Inc. $UPI.ca Names Frank Carnevale as Chief Growth Officer $SNE $MSFT $HON $SONA.ca

UPDATE – Else Nutrition $BABY.ca $BABYF Reports Third Quarter 2020 Results $BYND $VERY.ca $INGR $VEGN $TOFB

Posted by AGORACOM-JC at 10:03 AM on Tuesday, December 1st, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Else has achieved both a quality product and has established production lines in anticipation of significant ramp-up in sales during 2021.
  • In Q3 the company focused on: preparing the product for an initial soft launch into the U.S. markets via online and in retail channels, growing the brand awareness and obtaining the funding necessary for full-scale commercialization of the product line.
  • The Company completed the first two (2) commercial manufacturing runs of Else Complete Nutrition for Toddlers powder product.The Company launched online sales in North America on www.elsenutrition.com and on Amazon.com.
  • In October, the Company completed a C$25.7 million financing (the financing closed on October).

VANCOUVER, BC , Nov. 30, 2020 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY ) (OTCQX: BABYF ) (FSE: 0YF ) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company , today announced results for its third quarter ended September 30, 2020 .

The following will summarize our major achievements in the third quarter of 2020, as well as our business. Full financial results can be found in the Company News section of our website at https://elsenutrition.com/pages/investor-relations .

Q3 2020 Financial Highlights

  • Else has achieved both a quality product and has established production lines in anticipation of significant ramp-up in sales during 2021.
  • In Q3 the company focused on: preparing the product for an initial soft launch into the U.S. markets via online and in retail channels, growing the brand awareness and obtaining the funding necessary for full-scale commercialization of the product line.
  • The Company completed the first two (2) commercial manufacturing runs of Else Complete Nutrition for Toddlers powder product.
  • The Company launched online sales in North America on www.elsenutrition.com and on Amazon.com.
  • In October, the Company completed a C$25.7 million financing (the financing closed on October).
  • Operating loss was C$2,779 thousand , compared to C$1,056 thousand in the third quarter of 2019.
  • Net loss was C$3,930 thousand , or C$0.05 per share, compared to C$1,058 thousand , or C$0.02 per share in the third quarter of 2019.
  • Cash flow used for operating activities was C$2,965 thousand , compared to C$2,089 thousand in the third quarter of 2019.
  • Cash position was C$5.1 million as of September 30, 2020 (does not reflect the October financing for C$25.7 million ).

Nine Months Financial Highlights

The company started its operation in June 2019 so there are no comparable figures from 2019.

  • Operating loss was C$5,578 thousand .
  • Net loss was C$10,076 thousand , or C$0.13 per share.
  • Cash flow used for operating activities in the first nine months of 2020 was C$5,612 thousand .

Hamutal Yitzhak , Else CEO, commented: “I am very proud of our achievements this quarter. Although COVID-19 caused a slowdown on many fronts, we succeeded to complete two commercial manufacturing runs, package our product, launch our marketing campaign and start selling our revolutionary Plant-Based Complete Nutrition for Toddlers product in North America on our e-store and on Amazon.com. We also made significant progress on many other fronts, including the hiring of several retail brokers, listing on several natural food retail chains, onboarding to KeHE distributors, product development, clinical research, and more. By the end of the quarter we also completed our third and largest funding round ( C$25.7 million ), securing funds for operations for the next 18 months. We are very happy with the growth rate of our online sales since we launched, and with the progress we are making in the retail channel.”

Impact of COVID-19

We experience the effect of the pandemic in all areas of our business, from delays in raw material deliveries, to clinical and product development projects. Due to lockdowns and other COVID-19 related measures all our business meeting, marketing events, conferences and expos were either canceled or turned virtual, slowing down the pace of our business development efforts.

Revenue Distribution for Q3 2020

The Baby Snacks business line in Israel represented 44%, Baby Bottles and Accessories business line in Israel represented 26% and the Else Formula business represented 30% of total revenues.

As we started selling our Else Complete Nutrition For Toddler products (singles and 4-packs of 22oz cans of powder) online on our e-store ( www.elsenutrition.com ) on August 12 , our revenue from this channel represent the first few weeks of sales only, and amounted to C$109 thousand .

We started selling the same products also on Amazon.com on September 20 , and during these few days we completed well over 100 first sales which amounted to $C5 thousand .
Sells to retail stores did not commence in Q3, so no revenue was recorded yet from this channel.

Revenue Distribution for Nine Months 2020

The Baby Snacks business line in Israel represented 44%, Baby Bottles and Accessories business line in Israel represented 43% and the Else Formula business represented 13% of total revenues.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board  members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies,  and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents.  Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate.  Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements.  Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

View original content to download multimedia: http://www.prnewswire.com/news-releases/update—else-nutrition-reports-third-quarter-2020-results-301182718.html

SOURCE Else Nutrition Holdings Inc.

Tags: , , , , , , ,
Posted in Else Nutrition Holdings Inc. | Comments Off on UPDATE – Else Nutrition $BABY.ca $BABYF Reports Third Quarter 2020 Results $BYND $VERY.ca $INGR $VEGN $TOFB

Blockchain Foundry $BCFN.ca Reports Q3 2020 Financial Results $HUT.ca $BITF.ca $GLXY.ca $HIVE.ca $VYGR.ca

Posted by AGORACOM-JC at 9:34 AM on Tuesday, December 1st, 2020
http://blog.agoracom.com/wp-content/uploads/2020/10/blockchain-foundry-square.png

TORONTO, Dec. 01, 2020 – Blockchain Foundry Inc. (“BCF” or the “Company”) (CSE:BCFN), a leading North American blockchain development firm, is pleased to report its financial results for the three and nine months ended September 30, 2020. The Company’s full Financial Statements and Management Discussion & Analysis (“MD&A”) are available at www.sedar.com . All amounts are reported in Canadian dollars unless otherwise stated.

Financial Highlights

The following table summarizes revenue and net income (loss) for the three and nine months ended September 30, 2020 and September 30, 2019.

 Three months ended
 September 30,
2020		Three months ended
September 30,
2019		ChangePercentage
Change
Revenue227 , 410214,74412,6666%
Net Income74 , 33438,93535,39991%
     
 Nine months ended
 September 30,
2020		Nine months ended
September 30,
2019		ChangePercentage
Change
Revenue1,124,081526,714597,367113%
Net Income (Loss)141,974(467,322)609,296not meaningful

“In Q3 2020, BCF achieved positive net income and an increase in revenue compared with Q3 2019. This outcome was a direct result of increased client development activity as well as growing market acceptance of blockchain technology. The Company has five active clients in various project stages, and our pipeline is robust. We have also taken the opportunity to capitalize the business over the last few months. We are well positioned to continue expanding our consulting business and begin to explore product opportunities that take advantage of our significant expertise in the blockchain space,” said Dan Wasyluk, CEO of Blockchain Foundry.

Outlook

The Company continues to develop its suite of blockchain infrastructure technology products and build its blockchain development and advisory business.

On the product side, BCF is building core technology to enable highly scalable, low cost, high speed blockchain transactions (Z-DAG), allow users to incorporate multiple blockchain systems within the same project (Syscoin-Ethereum bridge), and initialize custom blockchain tokens (Spark Wallet). BCF’s technology infrastructure is suitable for a variety of use cases where speed, scalability, fees and security are important factors, including stablecoin projects, loyalty applications, digital identities, and remittance services.

On the advisory side, BCF endeavours to work with clients who share the same priorities and vision for what blockchain technology can achieve for governments, businesses and consumers. To date, BCF has worked with clients across industries including digital identity, financial services and token wallet and development infrastructure.

Q 3 2020 Business Highlights and Subsequent Events

  • Entered into a blockchain development agreement with NIX Platform. The agreement has a duration of approximately 6 months and a value of approximately $60,000. For more information please see the Company’s press release dated September 1, 2020.
  • Entered into a blockchain development agreement with a GDPR compliance solution provider. The initial phase of the agreement has a duration of approximately 4 weeks and a value of approximately $50,000. For more information please see the Company’s press release dated October 5, 2020.
  • Entered into an agreement for a drawdown equity financing facility of up to $4 million over a 24-month period with Alumina Partners (Ontario) Ltd., a subsidiary of Alumina Partners LLC, a New York-based private equity firm. Subsequently, the Company has drawn down three tranches under this agreement for total gross proceeds of $450,000. For more information please see the Company’s press releases dated October 6, 2020; November 10, 2020; and November 30, 2020.

About Blockchain Foundry Inc.

Blockchain Foundry develops and commercializes blockchain-based business solutions and provides consulting services to corporate clients seeking to incorporate blockchain technology into their businesses.

Blockchain Foundry Contact Information:

Chris Marsh
President
[email protected]
(647) 330-4572

Forward-Looking Information

Certain portions of this press release contain “forward-looking information” within the meaning of applicable Canadian securities legislation, which is also referred to as “forward-looking statements”, which may not be based on historical fact. Wherever possible, words such as “will”, “plans,” “expects,” “targets,” “continues”, “estimates,” “scheduled,” “anticipates,” “believes,” “intends,” “may,” “could,” “would” or might, and the negative of such expressions or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved, have been used to identify forward-looking information.

Forward-looking statements should not be read as guarantees of future events, future performance or results, and will not necessarily be accurate indicators of the times at, or by which, such events, performance or results will be achieved, if achieved at all. Readers should not place undue reliance on such forward-looking statements, as they reflect management’s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BCF are inherently subject to significant business, economic, regulatory, competitive, political and social uncertainties, and contingencies. Many factors could cause BCF’s actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. Although BCF has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are made as of the date hereof and, accordingly, are subject to change after such date. BCF disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Tags: , , , , , , , ,
Posted in All Recent Posts, Blockchain Foundry Inc. | Comments Off on Blockchain Foundry $BCFN.ca Reports Q3 2020 Financial Results $HUT.ca $BITF.ca $GLXY.ca $HIVE.ca $VYGR.ca

Plantx $VEGA.ca Announces Formation of a Medical Advisory Board and Non-Brokered Private Placement $BYND $TSN $CAG $FMCI $VERY $MEAT

Posted by AGORACOM-JC at 8:56 AM on Tuesday, December 1st, 2020
PlantX | LinkedIn
  • Announced it will form a medical advisory board composed of doctors and specialists from around the world to better educate the Company and the public on the health benefits of a plant-based lifestyle.
  • “In our mission to educate the public on the benefits of a plant-based lifestyle, we value the guidance of experts in the medical and science communities,” said Sean Dollinger , PlantX founder. “We look forward to working with our medical advisory board and using their recommendations to make PlantX a leader in the plant-based industry.”

VANCOUVER, BC , Dec. 1, 2020 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) is pleased to announce it will form a medical advisory board (” Medical Advisory Board “) composed of doctors and specialists from around the world to better educate the Company and the public on the health benefits of a plant-based lifestyle.

“In our mission to educate the public on the benefits of a plant-based lifestyle, we value the guidance of experts in the medical and science communities,” said Sean Dollinger , PlantX founder. “We look forward to working with our medical advisory board and using their recommendations to make PlantX a leader in the plant-based industry.”

The Medical Advisory Board will meet with PlantX once a month to review its products, meals, recipes and plants, and then make recommendations on how each will affect consumers’ health and wellness. The Medical Advisory Board will also discuss advancements in the plant-based industry and how the Company can capitalize on such advancements.

As a company promoting health, wellness and the benefits of a plant-based lifestyle, PlantX is making an effort to always have the most accurate and up-to-date information to make its online platform the preferred resource for the plant-based community. The Company’s customers will be encouraged to write in with questions, some of which will be answered by members of the Medical Advisory Board in upcoming blogs and podcasts to be made available on www.PlantX.com and www.PlantX.ca .

PlantX Medical Advisory Board

The Medical Advisory Board will consist of the following members:

Thomas A. Burdon , MD , is a Professor of Cardiothoracic Surgery at Stanford University and Chief of Surgery at the VA Palo Alto in California . He is an active surgeon and also supervises more than 150 staff that perform 6,000 surgical cases a year. Dr. Burdon’s commitment to improving the quality of life for his patients encompasses corrective and palliative surgical techniques, as well as providing dietary information and other methods to ameliorate and improve lifestyle habits. He is known by his colleagues and patients for the “Dr. Burdon Diet”, which has helped many in his work environment.

Dr. Katie Cooper is a doctor of psychology based out of London, England , and the author of the book Plant Therapy , which focuses on the well-being benefits of plants and the negative effects that an indoor lifestyle can have on mental health. After seeing how powerful plants could be as therapeutic tools with clients, Dr. Cooper went on to launch Bloomboxclub Limited, a successful plant subscription service in the UK, which is now a part of the PlantX family.

Edward Tam , MD, FRCPC, is a clinical hepatologist. His full time clinical practice is in Vancouver, BC , where he is also active in clinical research, teaching, education, and community outreach. He has a focused interest in the area of non-alcoholic fatty liver disease, including the intersection of how lifestyle and pharmacotherapeutic interventions may address this growing epidemic.

Paul Gross , MD, is a family physician working in downtown Vancouver . He completed medical school at McGill University and residency at St. Paul’s Hospital. Most of his clinical practice is concentrated at Spectrum Health, a multidisciplinary primary care clinic in downtown Vancouver that provides full-service care with an emphasis on the LGBTQ community.

Eva Weinlander , MD, is a Clinical Professor in the Department of Medicine, Division of Primary Care and Population Health at Stanford Health Care. She is a seasoned family medicine physician with a passion for high-quality primary care, medical education, primary care research and healthcare professional wellness.

“At PlantX, we want everyone to have access to the important information regarding health and wellness so they can implement it into their lives,” said Julia Frank , PlantX CEO. “Having medical professionals reinforce the benefits of plant-based living will only further what we can do as a company.”

“I am so excited about the opportunity to partner with the PlantX community, to share my conviction on the power of a healthy lifestyle and provide thoughtful and informed recommendations on how best to support that exploration, regardless of where one is in that journey,” said Dr. Eva Weinlander .

PlantX will continue to expand its verticals on both its Canadian and U.S. e-commerce platforms, with plans to globally grow its platforms and offerings in its promotion of plant-based health, wellness, lifestyles and education.

Non-Brokered Private Placement

The Company is also pleased to announce that it intends to complete a non-brokered private placement of up to 18,181,818 units of the Company (” Units “) at a price of CAD$0.55 per Unit for gross proceeds of up to CAD$10,000,000 (the ” Offering “). In addition, the Company may, at its sole discretion, issue an over-allotment of up to 2,727,273 Units for additional gross proceeds of up to CAD$1,500,000 should demand for the Offering prove higher than expected.

Each Unit will be comprised of one (1) common share (a ” Common Share “) of the Company and one (1) Common Share purchase warrant of the Company (a ” Warrant “). Each Warrant will entitle the holder to acquire one (1) Common Share of the Company for a period of 24 months from the date of issuance of the Warrant (the ” Warrant  Expiry Date “), at an exercise price of CAD$0.75 . In the event that the trading price of the Common Shares on the Canadian Securities Exchange (or such other Canadian stock exchange on which the Common Shares are listed for trading) equals or exceeds CAD$2.00 per Common Share for any period of 10 consecutive trading days, the Company may, at its option, within 10 business days following such 10-day period, accelerate the Warrant Expiry Date by issuing a press release (a ” Warrant Acceleration Press Release “), and, in such case, the Warrant Expiry Date shall be deemed to be 5:00 p.m. ( Vancouver time) on the 30th day following the issuance of the Warrant Acceleration Press Release.

The Company intends to use the net proceeds from the Offering for business operations and expansion of its business, and for general working capital purposes. The Offering may close in tranches and will be led by PlantX founder, Sean Dollinger , who will commit CAD$500,000 towards the Offering.

Although the Offering will be non-brokered, the Company may, as compensation to dealers and individuals that introduce subscribers to the Company (each a ” Finder “), and subject to regulatory approval: (i) pay a cash finder’s fee to each Finder equal to 7% of the aggregate gross proceeds of the subscribers introduced to the Company by such Finder; and (ii) issue non-transferable Common Share purchase warrants to each Finder (with terms identical to the Warrants issued under the Offering) equal to 7% of the aggregate Units of the subscribers introduced to the Company by such Finder.

The securities issued in connection with the Offering will be subject to a four-month hold period, in accordance with applicable securities laws.

About PlantX Life Inc.

As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant-based. With its fast growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing, and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs, and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle, and thriving in a longer, healthier, and happier life.

The Company website is http://investor.PlantX.com/ .

Forward Looking-Formation

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes statements relating to the expected formation of the Medical Advisory Board, the Company becoming a leader in the plant-based industry, the frequency of meetings of the Medical Advisory Board, the Medical Advisory Board answering PlantX customers’ questions in upcoming blogs and podcasts, the expected completion of the Offering, the expected terms and size of the Offering, PlantX founder, Sean Dollinger , committing CAD$500,000 towards the Offering, the proposed use of proceeds under the Offering and the business and strategic plans of the Company.

By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; a limited operating history, the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Additional risk factors can also be found in the Company’s continuous disclosure documents which have been filed on SEDAR and can be accessed at www.sedar.com . Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

SOURCE PlantX Life Inc.

Tags: , , , , , , , , , , ,
Posted in PlantX Life Inc. | Comments Off on Plantx $VEGA.ca Announces Formation of a Medical Advisory Board and Non-Brokered Private Placement $BYND $TSN $CAG $FMCI $VERY $MEAT

Peak $PKK.ca $PKKFF Signs Agreement with Italian Retailer Gruppo Coin to Help Finance Online Sales in China $DELX.ca $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca $IDK.ca

Posted by AGORACOM-JC at 7:42 AM on Tuesday, December 1st, 2020
Peak Fintech Group (@PEAK_Fintech) | Twitter
  • Announced that it has signed an agreement with high-end Italian retailer Gruppo Coin (“Coin”) to provide short-term loans to Coin’s social-media-influencer online sales partners.
  • Coin (https://en.coin.it/), Italy’s largest chain of department stores, was one of the first foreign retailers to recognize and leverage the power of social media influencers to sell their products in the world’s largest retail market.
  • Chinese influencers are using popular social media platforms such as TikTok, Sina Weibo and WeChat to revolutionize online retail sales. They create entertaining shows broadcasted on the platforms during which they promote and sell products with which they are associated.
  • A show will typically cost $1,000 to $10,000 to produce, including promoting it to followers, detailing the products and the limited quantities available for the show in order to create a buzz and the FOMO (fear of missing out) factor with their followers

Montreal, Quebec–(December 1, 2020) – Peak Fintech Group Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that it has signed an agreement with high-end Italian retailer Gruppo Coin (“Coin”) to provide short-term loans to Coin’s social-media-influencer online sales partners.

Coin (https://en.coin.it/), Italy’s largest chain of department stores, was one of the first foreign retailers to recognize and leverage the power of social media influencers to sell their products in the world’s largest retail market. Chinese influencers are using popular social media platforms such as TikTok, Sina Weibo and WeChat to revolutionize online retail sales. They create entertaining shows broadcasted on the platforms during which they promote and sell products with which they are associated.

A show will typically cost $1,000 to $10,000 to produce, including promoting it to followers, detailing the products and the limited quantities available for the show in order to create a buzz and the FOMO (fear of missing out) factor with their followers. On average, each influencer will produce about 250 shows per year. The average show typically lasts 3 to 4 hours and offers a variety of products. Top influencers are usually able to sell out their inventory of a particular product within the first 10 minutes of the product being presented. Many influencers have achieved celebrity status, and this is rapidly becoming the preferred way to sell a variety of products in China, from cosmetics to clothing to small appliances and everything in between. In addition to the cost of producing the shows, the influencers must provide their large retail partners with a deposit of 20% to 30% of the value of the products they expect to sell for each show. This is where Peak and the Cubeler Lending Hub come into the equation. With today’s announced agreement, Coin’s influencer partners will be eligible to have the cost of producing their shows, their required cash deposits and their entire product orders financed through the Lending Hub. Peak will earn its customary ~ 2% fee of the value of the loans provided for facilitating the transactions.

“We’ve been studying this space for months, identifying some of the top influencers and brand ambassadors on China’s top social media platforms,” commented Peak China CEO Liang Qiu. “We now have a network of almost 55,000 influencers, each either with their own e-Shops or affiliated with at least one e-Shop, over 120M combined followers and a proven track record of being able to effectively move products. With a network of followers more than 3 times larger than the entire Canadian population, we believe we’re well positioned to talk to virtually any retailer or brand around the world to offer an effective gateway into the Chinese retail space,” concluded Mr. Qiu.

“One of Peak’s objectives has always been to serve as a bridge that connects North American investors and businesses to China,” said Peak CEO Johnson Joseph. “We’ve been working very hard behind the scenes for quite a while now on a way to help Canadian businesses either do more business in China or gain access to the Chinese market. Although the agreement announced today is not with a Canadian company, it certainly sets the stage for us to sign similar agreements with Canadian retailers. Our network of influencers is already excited about the prospects of selling ice wine and a variety of uniquely Canadian products not typically available in China. By capitalizing on the power of social media, I think we’re once again proving our ability to innovate and think outside the box when it comes to the many ways in which we can use the Lending Hub for the benefit of small businesses and entrepreneurs.”

Wall Street Reporter’s NEXT SUPER STOCK Livestream – December 3, 2020

Peak will be a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK livestream conference on Thursday, December 3, 2020 at 12:30pm EST. CEO Johnson Joseph will discuss Peak’s agreement with Gruppo Coin, what it means for the Company going forward from an international standpoint and answer investor audience questions. Those interested can click the following link to register and join the livestream: Next Super Stock Livestream Registration.

About Peak Fintech Group Inc.:

Peak Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://www.peakfintechgroup.com

For more information, please contact:

CHF Capital Markets
Cathy Hume, CEO
416-868-1079 ext.: 251
[email protected]

Peak Fintech Group Inc.
Johnson Joseph, President and CEO
514-340-7775 ext.: 501
[email protected]

Twitter: @peakfintech
Facebook: @peakfintech
LinkedIn: Peak Fintech
YouTube: Peak Fintech


Forward-Looking Statements / Information:

This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.

Tags: , , , , , , , , ,
Posted in All Recent Posts, Featured, Peak Fintech Group | Comments Off on Peak $PKK.ca $PKKFF Signs Agreement with Italian Retailer Gruppo Coin to Help Finance Online Sales in China $DELX.ca $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca $IDK.ca

Loop Insights $MTRX.ca $RACMF Achieves 100% Success in Delivering First Ever Fully Integrated “Venue Bubble” in Live Environments at #NCAA College Basketball Tournaments. Live Demonstrations Lead to Significant Discussions About Largest North American Sporting Events in 2021

Posted by AGORACOM-JC at 7:32 AM on Tuesday, December 1st, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png

Success of Venue Bubble Solution in Las Vegas Has Also Created Visibility and Opportunity for Loop Travel Bubble Solutions

  • Announced the successful execution of its “Venue Bubble” solution in two separate live environments hosting NCAA Division 1 basketball teams.
  • The Loop Insights Venue Bubble solution was 100% successful in containing the bubble.
  • Moreover, the system did not suffer any outages and user experiences proved to be as seamless as anticipated, leading to overall satisfaction levels surpassing participant expectations and even Loop’s loftiest internal expectations.

VANCOUVER, British Columbia, Dec. 01, 2020 — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick and mortar space, is pleased to announce the successful execution of its “Venue Bubble” solution in two separate live environments hosting NCAA Division 1 basketball teams.

Loop Insights CEO Rob Anson stated, “There is simply no way to overstate the implications of our live environment Venue Bubble successes in Florida and Las Vegas over the past 10 days. With the whole world watching, including professional sports leagues and teams, college sports leagues and teams, world-renown venues and hospitality companies, Loop hit it out of the park and provided the world with the empirical data necessary to demonstrate our bubble solution is nothing short of world-class. To this end, we have already commenced significant discussions regarding the possibility of Loop protecting and helping to re-open some of North America’s largest sporting events in 2021.”

On October 8, 2020, Loop Insights announced it was selected as the Premier Venue Tracing and Fan Engagement Solution for NCAA College Basketball #VegasBubble in Las Vegas , where games are being played at MGM Grand Garden Arena, Mandalay Bay Events Center, and T-Mobile Arena between November 25 and December 22, 2020.

On November 9, 2020, Loop Insights announced it would Implement the First-Ever Fully Integrated “Venue Bubble” ( End-To-End Testing, Contact Tracing, and Alert Notifications) at the #BeachBubble NCAA College Basketball Tournament in Fort Myers, Florida , hosting 14 NCAA Division I men’s and women’s basketball teams in November and December that are playing at both Hertz Arena and Alico Arena (FGCU) while lodging at the Hyatt Regency.

The #BeachBubble implementation represented the first-ever end-to-end COVID-19 venue solution in a live environment and a major industry milestone given the global demand for venue solutions from enterprise-level organizations around the world. It was naturally extended to #VegasBubble.

bdG Sports CEO, Brooks Downing stated, “We are very excited with the performance and success of both Fort Myers and the Las Vegas Bubbles. The Loop Insights platform provided a great level of security while providing a very user-friendly experience for our participants. We look forward to working alongside Loop in upcoming future events.”

DATA CONFIRMS 100% SUCCESS AT BOTH #BEACHBUBBLE AND #VEGASBUBBLE TOURNAMENTS

With the #BeachBubble tournament having commenced earlier, the following interim statistics from that specific event can be shared with the public, similarities to which are also being generated at #VegasBubble.

Total Locations – 14

Total Enrolled Users – 553

Total Check-Ins – 3,830

Contact Tracing Checks – 2 reports had to be generated for potential infected cases, with tests confirming both were negative.

Conclusion – The Loop Insights Venue Bubble solution was 100% successful in containing the bubble. Moreover, the system did not suffer any outages and user experiences proved to be as seamless as anticipated, leading to overall satisfaction levels surpassing participant expectations and even Loop’s loftiest internal expectations.

SUCCESS OF VENUE BUBBLES CREATES SIGNIFICANT VISIBILITY AND OPPORTUNITY FOR LOOP #TRAVELBUBBLE SOLUTION SUPPORTED BY APPLE AND GOOGLE WALLET

As the resort convention capital of the world, the #VegasBubble provided Loop with the best possible opportunity to showcase its #TravelBubble solution for the global hospitality and travel industry, the latter of which is set to lose $USD 3.3 Trillion as a result of COVID-19.

To this end, Loop has completed all development and applications for the successful launch of its #TravelBubble solution that is completely embedded into one simple user interface – supported by Apple and Google wallet. Specifically, Loop provides a digital Wallet to users and assigns a digital ID to each user for the highest levels of security. Travelers are then able to upload COVID-19 testing results, vaccination certificates, boarding passes, airline loyalty rewards or points, travel insurance, driver’s license, and payments in one interface. 

LOOP IS FIRST TO MARKET WITH OPERATIONAL PLATFORM  

This complete and ready to deploy solution has garnered greater attention, as a result of the Company’s Venue Bubble success, from large global players who are only beginning to build their solutions, such as IATA, aiming to launch a cross-border solution in the first quarter of 2021. 

Loop not only is first to market with a complete operational platform built for deployment, it is also the first to successfully execute its solutions in a large, active, and live environment thanks to the success of the #BeachBubble and #VegasBubble. 

This is critical given the fact airlines, who can no longer wait for governments to scale back blanket quarantines to re-build their businesses, have taken the lead to partner directly with hotels and destinations to launch their own private bubbles. 

Rob Anson stated, “We are bringing a plug-and-play solution that can plug into any existing platform today. Recent high-level discussions within the airline industry confirm our advanced level of preparedness. Furthermore, we also meet the needs of the various travel bubbles and governments with public health officials looking to endorse the re-opening of economies, including the safe reopening of borders.” 

As a result, Loop believes an exponential opportunity to license its entire platform or pieces of it to many potential clients such as IATA, Hotel Chains, Airlines, and Government. 

LOOP TRAVEL BUBBLE SOLUTION SOLVES CURRENT QUARANTINE REQUIREMENTS THAT ARE SHUTTING DOWN INTERNATIONAL TRAVEL

As a result of the COVID-19 Pandemic, mandatory 14-day quarantine periods, and the lack of any travel bubble solutions that could reliably track and mitigate the global spread of the virus by plane or cruise ship, countries have been forced to take drastic measures that are leading to significant damage of the global travel industry.

Specifically, as of today, travel restrictions by country are as follows:

50 countries are completely closed

123 countries are partially open with MANDATORY quarantine upon arrival

(Source – https://www.ca.kayak.com/travel-restrictions)

With governments beginning to use rapid testing as a means of limiting the risks of COVID-19 importation when re-opening their borders to travelers without quarantine measures, Loop provides a means to ensure closed-loop COVID-19 testing and proof of vaccination is available for all international travelers, as well as, the information flow infrastructure needed to enable it.

$3.3 TRILLION IN LOSSES FOR GLOBAL TOURISM INDUSTRY

Without a solution to replace the drastic travel measures currently in place around the world, the United Nations Conference on Trade and Development (UNCTAD) reported that COVID-19 may cost the world tourism sector losses of US$ 3.3 trillion.

In Canada alone, according to Statista, the Canadian tourism industry contributed close to $40 billion to the economy in 2019. This year, the COVID-19 pandemic has had devastating consequences for the industry.

This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions, and engagement with management https://agoracom.com/ir/LoopInsights

About Loop Insights : Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.

For more information, please contact:

Loop Insights Inc. LOOP Website : www.loopinsights.ai
Rob Anson, CEO Facebook: @ LoopInsights
T : +1 877-754-5336 Ext. 4 Twitter: @ LoopInsights
E : [email protected] LinkedIn: @ LoopInsights

Forward-Looking Statements/Information:  

This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.  

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.   

Tags: , , , , , , , , , , , , , ,
Posted in Featured, Loop Insights Inc. | Comments Off on Loop Insights $MTRX.ca $RACMF Achieves 100% Success in Delivering First Ever Fully Integrated “Venue Bubble” in Live Environments at #NCAA College Basketball Tournaments. Live Demonstrations Lead to Significant Discussions About Largest North American Sporting Events in 2021

« Older Entries
Newer Entries »